Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Retained Earnings (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Retained Earnings for 5 consecutive years, with -$199.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 78645.35% year-over-year to -$199.3 million, compared with a TTM value of -$199.3 million through Sep 2025, down 78645.35%, and an annual FY2024 reading of $253734.0, changed 0.0% over the prior year.
  • Retained Earnings was -$199.3 million for Q3 2025 at Xenetic Biosciences, roughly flat from -$198.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $253734.0 in Q1 2023 and bottomed at -$199.3 million in Q3 2025.
  • Average Retained Earnings over 3 years is -$71.4 million, with a median of $253734.0 recorded in 2023.
  • The sharpest move saw Retained Earnings skyrocketed 100.13% in 2024, then crashed 78645.35% in 2025.
  • Year by year, Retained Earnings stood at $253734.0 in 2023, then changed by 0.0% to $253734.0 in 2024, then plummeted by 78645.35% to -$199.3 million in 2025.
  • Business Quant data shows Retained Earnings for XBIO at -$199.3 million in Q3 2025, -$198.8 million in Q2 2025, and -$198.1 million in Q1 2025.